MALDI-TOF mass spectrometry and proteomics as phenotypic screening tools for anti-inflammatory drugs

Abstract

Phenotypic screening is a powerful technology to discover drug candidates in physiologically relevant systems without prior knowledge of molecular targets; however, mass spectrometry (MS) remains underutilised as readout strategy. In this proof-of-concept study, we developed and evaluated two complementary MS-based phenotypic screening approaches to identify anti-inflammatory compounds in human induced pluripotent stem cell-derived macrophages and compared them to a conventional targeted cytokine profiling assay. First, we established a novel MALDI-TOF MS fingerprinting strategy that effectively distinguished macrophage phenotypes, identified phenotype-specific biomarkers, and maintained high-throughput capabilities while reducing cost. Secondly, we performed an in-depth LC-MS proteomic analysis using low cell input on an Evosep-timsTOF HT setup, providing rich molecular detail. Both MS-based approaches demonstrated large comparability with the cytokine assay, with a large proportion of hits overlapping. Notably, the proteomics workflow uniquely enabled deeper insight into inflammation pathway engagement, off-target effects, compound potency, and cytotoxicity. Together, these findings highlight the potential of MS-driven phenotypic screening to enhance early drug discovery by enabling efficient, informative, and cost-effective hit selection. O_FIG O_LINKSMALLFIG WIDTH=196 HEIGHT=200 SRC="FIGDIR/small/691706v1_ufig1.gif" ALT="Figure 1"> View larger version (59K): org.highwire.dtl.DTLVardef@c83cb7org.highwire.dtl.DTLVardef@a14d4org.highwire.dtl.DTLVardef@1dda6d7org.highwire.dtl.DTLVardef@f47564_HPS_FORMAT_FIGEXP M_FIG C_FIG